Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 9/20 | 0.57 |
| ▸ | CA12 | O43570 | 8/20 | 0.57 |
| ▸ | CA2 | P00918 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.57 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.57 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.57 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.57 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.57 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2677005 | 0.89 | SMN1; SMN2 (0.50) | CA9CA12CA2SMN1; SMN2RAB9A | |
| SCHEMBL3200608 | 0.87 | VCAM1 (0.49) | CA9CA12CA2SMN1; SMN2RAB9A | |
| SCHEMBL3201245 | 0.86 | CNR2 (0.48) | CA9CA12CA2SMN1; SMN2RAB9A | |
| SCHEMBL3193841 | 0.86 | CNR2 (0.48) | CA9CA12CA2SMN1; SMN2RAB9A | |
| SCHEMBL3201690 | 0.86 | CNR2 (0.48) | CA9CA12CA2SMN1; SMN2RAB9A | |
| SCHEMBL3193958 | 0.86 | CNR2 (0.48) | CA9CA12CA2SMN1; SMN2RAB9A | |
| SCHEMBL3196045 | 0.86 | CNR2 (0.48) | CA9CA12CA2SMN1; SMN2RAB9A | |
| SCHEMBL3198478 | 0.86 | CNR2 (0.48) | CA9CA12CA2SMN1; SMN2RAB9A | |
| SCHEMBL1085990 | 0.84 | LMNA (0.64) | SMN1; SMN2RAB9ALMNAMEN1KMT2A | |
| SCHEMBL11418681 | 0.82 | KDM4E (0.51) | CA9CA12CA2SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 527 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962607-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-24 | — | — | US | claimed |
| EP-2421823-B1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-14 | — | — | EP | claimed |
| US-20140243305-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2014-08-28 | — | — | US | claimed |
| US-8445477-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-05-21 | — | — | US | claimed |
| EP-2421823-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| US-20100324012-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | claimed |
| WO-2010124086-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| US-20080312301-A1 | Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof | GRUENENTHAL GMBH (DE) | 2008-12-18 | — | — | US | claimed |
| EP-1893589-A1 | SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS | Grünenthal GmbH (DE) | 2008-03-05 | — | — | EP | claimed |
| EP-1576110-A4 | CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER | AVOLIX PHARMACEUTICALS (US) | 2007-11-07 | — | — | EP | claimed |
| WO-2006131296-A1 | SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS | Grünenthal GmbH (DE) | 2006-12-14 | — | — | WO | claimed |
| US-20060128742-A1 | Cell migration inhibiting compositions and methods and compositions for treating cancer | AVOLIX PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | claimed |
| EP-1576110-A2 | CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER | Avolix Pharmaceuticals (US) | 2005-09-21 | — | — | EP | claimed |
| WO-2003102153-A2 | CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER | AVOLIX PHARMACEUTICALS (US) | 2003-12-11 | — | — | WO | claimed |
| US-10961405-B2 | Fluorine-containing acetophenone derivative, fluroine based additive, curable composition including same, and cured product thereof | DIC CORPORATION (JP) | 2021-03-30 | — | — | US | disclosed |
| EP-1657286-B1 | Radiation curable ink jet ink, comprising a polymerisation initiation sensitising dye | FUJIFILM CORP (JP) | 2018-07-04 | — | — | EP | disclosed |
| US-9957402-B2 | Compound, active energy ray curable composition, cured article thereof, printing ink, and inkjet recording ink | DIC CORPORATION (JP) | 2018-05-01 | — | — | US | disclosed |
| EP-0710887-A1 | Photopolymerizable composition | FUJI PHOTO FILM CO., LTD. (JP) | 1996-05-08 | — | — | EP | disclosed |
| EP-0689575-A1 | ANTHRAQUINONES AS MARKING AGENTS FOR MINERAL OILS | BASF AG (DE) | 1996-01-03 | — | — | EP | disclosed |
| WO-1994021752-A1 | ANTHRAQUINONES AS MARKING AGENTS FOR MINERAL OILS | BASF AKTIENGESELLSCHAFT (DE) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312301-A1 | Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof | HTR5A, NPY5R, GRM5 | CA9 4777/4885CA12 4879/4885CA2 3102/4885 |
| US-20060128742-A1 | Cell migration inhibiting compositions and methods and compositions for treating cancer | MKI67, DCX, NUDC | CA9 171/4885CA12 556/4885CA2 1226/4885 |
| US-20140243305-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | CA9 1639/4885CA12 4272/4885CA2 2746/4885 |
| US-20100324012-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | CA9 1639/4885CA12 4272/4885CA2 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.